CAMBRIDGE, Mass., Jan. 4, 2022 /PRNewswire/ -- Nuvalent, Inc.
(Nasdaq: NUVL), a biopharmaceutical company focused on creating
precisely targeted therapies for clinically proven kinase
targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer,
will present at the 40th Annual J.P. Morgan Healthcare
Conference on Wednesday, January 12,
2022, at 11:15 a.m.
ET.
A live webcast will be available in the investor section of the
company's website at www.nuvalent.com, and archived for 30 days
following the presentation.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a biopharmaceutical company
focused on creating precisely targeted therapies
for patients with cancer, designed to overcome the limitations of
existing therapies for clinically proven kinase targets. Leveraging
deep expertise in chemistry and structure-based drug design, we
develop innovative small molecules that have the potential to
overcome resistance, minimize adverse events, address brain
metastases, and drive more durable responses. Nuvalent is advancing
a robust pipeline with parallel lead programs in ROS1-positive and
ALK-positive non-small cell lung cancer (NSCLC), along with
multiple discovery-stage research programs. We routinely post
information that may be important to investors on our website
at www.nuvalent.com. Follow us on Twitter (@nuvalent)
and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-present-at-the-40th-annual-jp-morgan-healthcare-conference-301453060.html
SOURCE Nuvalent, Inc.